TEL AVIV – The latest data from Israel shows a 94% decrease in symptomatic Covid-19 infections among 600,000 people who received two doses of Pfizer Inc. and BioNTech SE vaccine, providing important new insights to other countries when they roll out their own campaigns.
The vaccinated group was also 92% less likely to develop serious illness from the disease, according to a study by Clalit, Israel’s largest healthcare provider. Clalit compared 600,000 people who received the shots to a group of the same size who did not – in what was the country’s largest vaccine study to date.
Clalit said the survey, conducted with a team from Harvard University, included 430,000 people between the ages of 16 and 59 and 170,000 who were 60 or older. It was the first of its kind to show such a high level of efficacy for Pfizer’s vaccine for 70 years and over due to the limited scope of the clinical trials, according to the healthcare provider.
The study was conducted so that each vaccinated person was tested against an unvaccinated person who had a similar profile, including their risk level for infection, risk level for developing serious illness and general health.
“It is now clear that Pfizer’s coronavirus vaccine is incredibly effective in real life one week after the second dose, as found in the clinical study,” said Ran Balicer, Clalit’s Chief Innovation Officer and one of the study’s authors. , in a Hebrew statement published Sunday with the study. The vaccine is even more effective two weeks after the second shot, he added.
More Tags We Lovefull coverage auto insurance cost texas what state has the cheapest health insurance rates which is the best term life insurance policy car insurance for a day cost where is the cheapest auto insurance what is the best life insurance to buy in canada auto insurance companies in california auto insurance florida auto insurance companies in us average auto insurance cost california